{"id":"adalimumab-ab","safety":{"commonSideEffects":[{"rate":"12-15","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"1-3","effect":"Serious infections"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab blocks TNF-α, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By preventing TNF-α from binding to its receptors on immune cells, the drug suppresses the inflammatory cascade and reduces disease activity in conditions driven by excessive TNF-α signaling.","oneSentence":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:07.654Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT05460390","phase":"NA","title":"Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2022-10-26","conditions":"Rheumatoid Arthritis","enrollment":5},{"nctId":"NCT05527444","phase":"PHASE4","title":"The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-15","conditions":"Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT02896985","phase":"","title":"Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-16","conditions":"Crohn's Disease","enrollment":98},{"nctId":"NCT03217734","phase":"PHASE2, PHASE3","title":"MAP Study: Methotrexate and Adalimumab in Psoriasis","status":"COMPLETED","sponsor":"Jeffrey J Crowley MD","startDate":"2017-04-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT00851565","phase":"PHASE4","title":"Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy","status":"UNKNOWN","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2009-06","conditions":"Crohn's Disease","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adalimumab"],"phase":"marketed","status":"active","brandName":"Adalimumab Ab","genericName":"Adalimumab Ab","companyName":"Qilu Hospital of Shandong University","companyId":"qilu-hospital-of-shandong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}